Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ligand Pharmaceuticals (LGND) Operating Expenses (2016 - 2025)

Historic Operating Expenses for Ligand Pharmaceuticals (LGND) over the last 16 years, with Q3 2025 value amounting to $60.5 million.

  • Ligand Pharmaceuticals' Operating Expenses rose 2437.07% to $60.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $233.7 million, marking a year-over-year increase of 3849.62%. This contributed to the annual value of $189.7 million for FY2024, which is 5617.28% up from last year.
  • Ligand Pharmaceuticals' Operating Expenses amounted to $60.5 million in Q3 2025, which was up 2437.07% from $39.2 million recorded in Q2 2025.
  • In the past 5 years, Ligand Pharmaceuticals' Operating Expenses registered a high of $81.5 million during Q1 2025, and its lowest value of $24.9 million during Q2 2021.
  • Over the past 5 years, Ligand Pharmaceuticals' median Operating Expenses value was $39.2 million (recorded in 2025), while the average stood at $43.3 million.
  • As far as peak fluctuations go, Ligand Pharmaceuticals' Operating Expenses plummeted by 5536.53% in 2023, and later soared by 19135.05% in 2025.
  • Ligand Pharmaceuticals' Operating Expenses (Quarter) stood at $41.3 million in 2021, then surged by 70.74% to $70.5 million in 2022, then tumbled by 55.37% to $31.5 million in 2023, then skyrocketed by 66.72% to $52.4 million in 2024, then grew by 15.41% to $60.5 million in 2025.
  • Its last three reported values are $60.5 million in Q3 2025, $39.2 million for Q2 2025, and $81.5 million during Q1 2025.